Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles

Ther Deliv. 2016 Sep;7(9):649-55. doi: 10.4155/tde-2016-0045.

Abstract

The most common method for cancer treatment is chemotherapy. Multidrug resistance (MDR) is one of the major obstacles in chemotherapeutic treatment of many human cancers. One strategy to overcome this challenge is the delivery of anticancer drugs and siRNA simultaneously using nanoparticles. Mesoporous silica nanoparticles are one of the most popular nanoparticles for cargo delivery because of their intrinsic porosity. This paper highlights recent advances in codelivery of chemotherapeutic and siRNA with mesoporous silica nanoparticles for cancer therapy. In addition, synthesis and functionalization approaches of these nanoparticles are summarized. This review presents insight into the utilization of nanoparticles and combination therapy to achieve more promising results in chemotherapy.

Keywords: cancer; chemotherapy; codelivery; mesoporous silica nanoparticle; multidrug resistance; siRNA.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Drug Resistance, Multiple
  • Humans
  • Nanoparticles*
  • Neoplasms / drug therapy*
  • Porosity
  • RNA, Small Interfering / administration & dosage*
  • Silicon Dioxide*

Substances

  • Antineoplastic Agents
  • RNA, Small Interfering
  • Silicon Dioxide